tiprankstipranks
Trending News
More News >

Buy Rating for Mereo Biopharma Group Plc Driven by Promising Phase 3 Study of Setrusumab in Osteogenesis Imperfecta

Buy Rating for Mereo Biopharma Group Plc Driven by Promising Phase 3 Study of Setrusumab in Osteogenesis Imperfecta

Analyst Cory Jubinville, PhD of LifeSci Capital maintained a Buy rating on Mereo Biopharma Group Plc (MREOResearch Report), retaining the price target of $10.00.

Don’t Miss TipRanks’ Half-Year Sale

Cory Jubinville, PhD has given his Buy rating due to a combination of factors that highlight the potential of Mereo Biopharma Group Plc. The company is actively investigating setrusumab, an anti-sclerostin monoclonal antibody, in a Phase 3 study for osteogenesis imperfecta (OI), a rare genetic disorder with limited treatment options. This study, known as the Orbit study, is approaching its second interim analysis, which presents a favorable risk-reward profile.
The potential to stop the study early based on efficacy, if the primary endpoint of Annualized Fracture Rate is met at a statistically achievable threshold, adds to the investment appeal. Additionally, the ongoing research and upcoming discussions with experts in the field underscore the promising therapeutic strategy of sclerostin inhibition in OI, further supporting the Buy recommendation.

In another report released on April 9, Needham also maintained a Buy rating on the stock with a $7.00 price target.

Disclaimer & DisclosureReport an Issue

1